Zobrazeno 1 - 10
of 70
pro vyhledávání: '"Mohammad A Alzubi"'
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/ee72429637da4239b0711034cd2b1da2
Autor:
Narmeen S. Rashid, David C. Boyd, Amy L. Olex, Jacqueline M. Grible, Alex K. Duong, Mohammad A. Alzubi, Julia E. Altman, Tess J. Leftwich, Aaron D. Valentine, Nicole S. Hairr, Emily K. Zboril, Timothy M. Smith, Adam D. Pfefferle, Mikhail G. Dozmorov, J. Chuck Harrell
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-13 (2022)
Abstract The goals of this study were to identify transcriptomic changes that arise in basal-like breast cancer cells during the development of resistance to epidermal growth factor receptor inhibitors (EGFRi) and to identify drugs that are cytotoxic
Externí odkaz:
https://doaj.org/article/b6420fc492e5431b99d423a4fa959d96
Autor:
Mohammad A. Alzubi, Tia H. Turner, Amy L. Olex, Sahib S. Sohal, Nicholas P. Tobin, Susana G. Recio, Jonas Bergh, Thomas Hatschek, Joel S. Parker, Carol A. Sartorius, Charles M. Perou, Mikhail G. Dozmorov, J. Chuck Harrell
Publikováno v:
Breast Cancer Research, Vol 21, Iss 1, Pp 1-15 (2019)
Abstract Background The seed and soil hypothesis was proposed over a century ago to describe why cancer cells (seeds) grow in certain organs (soil). Since then, the genetic properties that define the cancer cells have been heavily investigated; howev
Externí odkaz:
https://doaj.org/article/4c6513371deb4dd18f222731bbba6ee5
Autor:
Melissa A. Maczis, Michael Maceyka, Michael R. Waters, Jason Newton, Manjulata Singh, Madisyn F. Rigsby, Tia H. Turner, Mohammad A. Alzubi, J. Chuck Harrell, Sheldon Milstien, Sarah Spiegel
Publikováno v:
Journal of Lipid Research, Vol 59, Iss 12, Pp 2297-2307 (2018)
In breast cancer, 17β-estradiol (E2) plays critical roles mainly by binding to its canonical receptor, estrogen receptor (ER) α66, and eliciting genomic effects. E2 also triggers rapid, nongenomic responses. E2 activates sphingosine kinase 1 (SphK1
Externí odkaz:
https://doaj.org/article/11add8e4d4e24b16b926a6081e7b3173
Autor:
Graeme F. Murray, Tia H. Turner, Daniel Guest, Kevin A. Leslie, Mohammad A. Alzubi, Senthil K. Radhakrishnan, J. Chuck Harrell, Jason Reed
Publikováno v:
Frontiers in Physics, Vol 7 (2019)
The development of resistance to initially successful cancer therapies is a major cause of the morbidity and mortality associated with cancer. Identifying evolving resistance at an early stage could inform clinical decision making to adapt therapies
Externí odkaz:
https://doaj.org/article/f4ce7a986b1045b697a7f7f2889700c6
Autor:
Xuxu Gou, Beom-Jun Kim, Meenakshi Anurag, Jonathan T. Lei, Meggie N. Young, Matthew V. Holt, Diana Fandino, Craig T. Vollert, Purba Singh, Mohammad A. Alzubi, Anna Malovannaya, Lacey E. Dobrolecki, Michael T. Lewis, Shunqiang Li, Charles E. Foulds, Matthew J. Ellis
Publikováno v:
Cancer Research.
Transcriptionally active ESR1 gene fusions (ESR1-TAF) are a potent cause of breast cancer endocrine therapy (ET) resistance. ESR1-TAFs are not directly druggable because the C-terminal estrogen/anti-estrogen binding domain is replaced with translocat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cd8a5e544fdf3311aaf43059e0465256
https://doi.org/10.1158/0008-5472.can-22-3484
https://doi.org/10.1158/0008-5472.can-22-3484
Autor:
Jennifer E. Koblinski, Nicholas P. Farrell, Kazuaki Takabe, Eriko Katsuta, Larisa Litovchick, Bin Hu, Madhavi Puchalapalli, Michael O. Idowu, Mayuri Shende, Vita Kraskauskiene, Pam J. Gigliotti, Joseph B. McGee Turner, Mikhail G. Dozmorov, J. Chuck Harrell, Mohammad A. Alzubi, Tia H. Turner, Samantha J. Katner, Erica J. Peterson, James D. Hampton
Triple-negative breast cancer (TNBC) is a subtype of breast cancer lacking targetable biomarkers. TNBC is known to be most aggressive and when metastatic is often drug-resistant and uncurable. Biomarkers predicting response to therapy improve treatme
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::62cc3ab448dff231d3ed792829c70fad
https://doi.org/10.1158/1535-7163.c.6543516.v1
https://doi.org/10.1158/1535-7163.c.6543516.v1
Autor:
Jennifer E. Koblinski, Nicholas P. Farrell, Kazuaki Takabe, Eriko Katsuta, Larisa Litovchick, Bin Hu, Madhavi Puchalapalli, Michael O. Idowu, Mayuri Shende, Vita Kraskauskiene, Pam J. Gigliotti, Joseph B. McGee Turner, Mikhail G. Dozmorov, J. Chuck Harrell, Mohammad A. Alzubi, Tia H. Turner, Samantha J. Katner, Erica J. Peterson, James D. Hampton
Supplemental Figures
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7a2f7049077650fd00573d93d611fd5b
https://doi.org/10.1158/1535-7163.22522884.v1
https://doi.org/10.1158/1535-7163.22522884.v1
Autor:
Madhavi Puchallapalli, Nicholas Farrell, Bin Hu, Mohammad A. Alzubi, Tia H. Turner, James D. Hampton, Larisa Litovchick, Vita Kraskauskiene, Samantha J. Katner, Jennifer E. Koblinski, Kazuaki Takabe, J. Chuck Harrell, Mayuri Shende, Joseph B. McGee Turner, Michael O. Idowu, Erica J. Peterson, Mikhail G. Dozmorov, Eriko Katsuta, Pamela J Gigliotti
Publikováno v:
Mol Cancer Ther
Triple-negative breast cancer (TNBC) is a subtype of breast cancer lacking targetable biomarkers. TNBC is known to be most aggressive and when metastatic is often drug-resistant and uncurable. Biomarkers predicting response to therapy improve treatme
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::528ef15740264f591daf293c796b626d
https://doi.org/10.1158/1535-7163.mct-20-0969
https://doi.org/10.1158/1535-7163.mct-20-0969
Autor:
Paul B. Fisher, Devanand Sarkar, Swadesh K. Das, Mohammad A. Alzubi, Xue-Ning Shen, Timothy P. Kegelman, Manny D. Bacolod, Luni Emdad, Bin Hu
Supplementary Figures Legends S1-S9.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d0bc2916f56f1f276344e2d7eac1045
https://doi.org/10.1158/0008-5472.22401977
https://doi.org/10.1158/0008-5472.22401977